Igm Biosciences Inc Revenue Growth Rates (IGMS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Igm Biosciences Inc   (NASDAQ: IGMS)
 

IGMS's Revenue Growth by Quarter and Year

Igm Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IGMS Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 143.62
1st Quarter March 0.00
FY 143.62





IGMS Revenue second quarter 2025 Y/Y Growth Comment
Igm Biosciences Inc achieved in the second quarter 2025, above Company average Revenue surge of 11389.84% year on year, to $ 143.62 millions.

According to the results reported in the second quarter 2025, Igm Biosciences Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Igm Biosciences Inc ' s Revenue doubling of 11389.84% ranks overall at the positon no. 2 in the second quarter 2025.


IGMS Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -17.27 % 2.8 % -
3rd Quarter September - 1.96 % - -
2nd Quarter June 11389.84 % - - -
1st Quarter March - - - -
FY   - 25.82 % 99.07 % -

Financial Statements
Igm Biosciences Inc 's second quarter 2025 Revenue $ 143.62 millions IGMS's Income Statement
Igm Biosciences Inc 's second quarter 2024 Revenue $ 1.25 millions Quarterly IGMS's Income Statement


IGMS Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 75 % 115.69 % -
3rd Quarter September - -58.4 % - -
2nd Quarter June - - - -
1st Quarter March - - -51.4 % -
FY (Year on Year)   - 25.82 % 99.07 % -


Back to IGMS Growth rate Comparisons >> Back to IGMS Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #2

Revenue Y/Y Growth Statistics
High Average Low
11353.19 % 2248.02 % -100 %
 
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #2
Revenue Y/Y Growth Statistics
High Average Low
11353.19 % 2248.02 % -100 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Igm Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IGMS's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IGMS's II. Quarter Q/Q Revenue Comment


Igm Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jun 30 2025 period, Igm Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Igm Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2025 period, Igm Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Igm Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IGMS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Capforce Inc 14,185.71%$ 14,185.714 millions
Igm Biosciences Inc 11,353.19%$ 11,353.190 millions


About Igm Biosciences Inc Revenue Growth Rates (IGMS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Igm Biosciences Inc (CIK 1496323).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-25-100885
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Igm Biosciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.